Rimegepant to Prevent Migraine Linked to Night Shifts in Hospital Workers

Trial details

Who runs it

Chinese PLA General Hospital

Trial code

NCT07918053

Record updated

5 November 2026

Original description

Background and Objectives:Read full original descriptionShow less

A Prospective, Open-label, Randomized, Two-period Crossover Study of Rimegepant for Intermittent / Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals

Background and Objectives:

Medical professionals frequently work night shifts and rotating schedules. Night shift work, accompanied by sleep deprivation and stress, is a significant trigger for migraine attacks. Traditional preventive migraine medications usually require continuous administration and gradual dose titration, making them unsuitable for short-term, intermittent prevention specifically during night shifts. Rimegepant, a small-molecule CGRP receptor antagonist orally disintegrating tablet, has a rapid onset of action and a relatively short half-life, making it suitable for intermittent administration (i.e., situational prevention) prior to predictable periods of high migraine risk.

This study aims to evaluate whether administering Rimegepant 75 mg orally within 2 hours before the start of a night shift and at the end of the night shift can effectively prevent moderate-to-severe migraine during the night shift and the 24-hour post-shift observation window.

Study Design:

This is a prospective, open-label, randomized, two-cycle crossover clinical study conducted in China. Approximately 260 eligible participants are planned to be enrolled.

After a 4-week screening/baseline observation period, participants will be randomized 1:1 to one of two treatment sequences:

Sequence A: Rimegepant situational preventive treatment in Treatment Period 1, followed by a 10-day washout period, and standard care in Treatment Period 2.

Sequence B: Standard care in Treatment Period 1, followed by a 10-day washout period, and Rimegepant situational preventive treatment in Treatment Period 2.

Each treatment period lasts 4 weeks. Subsequently, all participants will enter a 4-week open-label extension period to receive Rimegepant treatment.

Target Population:

Study Population: Clinicians or nurses aged 18-60 working in Chinese hospitals.

Key Inclusion Criteria: Diagnosis of migraine (with or without aura) according to ICHD-3 criteria; at least 1 migraine attack occurring in the night-shift-related observation window per month over the past 3 months; at least 1 moderate-to-severe migraine attack during the 4-week screening period; ability to complete the electronic diary (eDiary).

Key Exclusion Criteria: Patients with chronic migraine; history of hepatic or renal impairment; history of hypersensitivity to CGRP receptor antagonists; participation in another clinical study within the past 3 months; pregnant or breastfeeding women, etc.

Primary Outcome Measures:

Primary Endpoint: The mean number of moderate-to-severe migraine days per evaluable night-shift-related observation window during each 4-week treatment period (assessed via eDiary).

Key Secondary Endpoints: Mean headache/migraine days within the night-shift-related observation window; number of moderate-to-severe migraine attacks during the night shift; days of acute migraine medication use; and changes in scale scores including sleep quality (PSQI), quality of life (MSQoL), and headache impact (HIT-6).

Significance:

The results of this study are expected to provide a feasible, effective, and targeted situational preventive strategy for migraine for medical professionals, a high-risk occupational population, and to provide clinical evidence for migraine management in similar short-term high-risk scenarios.

Inclusion: Male or female, aged 18 to 60 years; Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria; Employed as a clinical doctor or nurse; self-reported at least 1 migraine attack occurring in the night-shift-related observation window per month over the past 3 months; and anticipated no substantial change in the night shift rotation cycle before study completion; At least one moderate-to-severe migraine attack occurring in the night-shift-related observation window during the 4-week screening period; Able to understand and comply with electronic diary entries, complete related scales, and provide written informed consent; The start times of two consecutive eligible night shifts must be separated by at least 4 calendar days (inclusive of the 4th day); Participants may continue medications with potential migraine-preventive effects, regardless of symptoms, provided the dose has been stable for at least 3 months (12 weeks) prior to the screening period and is not expected to change. (Excludes CGRP monoclonal antibodies or receptor antagonists).

Exclusion: Patient-reported history of hepatic or renal impairment; History of hypersensitivity to CGRP receptor antagonists; Participation in another clinical study within the past 3 months; Pregnant or breastfeeding women; Chronic migraine; Uncontrolled, unstable, or newly diagnosed cardiovascular disease (e.g., ischemic heart disease, coronary vasospasm, or cerebral ischemia); or participants who have had a myocardial infarction, acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), cardiac surgery, stroke, or transient ischemic attack (TIA) within 6 months prior to the screening period; Current or past diagnosis of schizophrenia, bipolar disorder, borderline personality disorder, or severe mood disorders including depression and anxiety; Concomitant use of other small-molecule CGRP receptor antagonists for acute treatment, or use of strong CYP3A4 inhibitors or strong/moderate CYP3A4 inducers, which may significantly affect rimegepant exposure; Current use of any CGRP-targeted preventive treatment, including monoclonal antibodies against CGRP or its receptor, and small-molecule CGRP receptor antagonists; Use of rimegepant outside the designated rimegepant treatment periods as situational preventive treatment, or as acute.

ClinicalTrials.gov NCT07918053